Cardiac antiplatelet therapy plays a crucial role in managing cardiovascular health by preventing blood clot formation, a common factor in heart-related issues. These therapeutic interventions primarily involve medications that inhibit platelet activity, reducing the risk of blood vessel blockages and potential heart events. Aspirin is a well-known antiplatelet agent widely used in cardiac care, working to hinder platelets from clumping together. Additionally, newer antiplatelet medications, such as clopidogrel and prasugrel, offer alternative options for individuals with specific cardiovascular conditions. The strategic use of antiplatelet therapy is tailored to each patient's unique medical profile, ensuring an effective and personalized approach to maintaining heart health. As ongoing research continues to uncover advancements in cardiovascular medicine, the role of cardiac antiplatelet therapy remains pivotal in the pursuit of comprehensive and targeted cardiovascular care
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation